In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been making waves in the biopharmaceutical industry with its strong portfolio of ...

Ratings has upgraded the issuer rating and senior unsecured notes ratings of global pharmaceutical company Eli Lilly and Company (NYSE:LLY) to Aa3 from A1. The Prime-1 short-term rating was affirmed.

Nico Chen’s rating is based on a combination of factors that highlight Eli Lilly & Co’s promising ... to positive developments in their drug pipeline, particularly the oral GLP-1 drug ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company has taken the GLP-1 supply chain too far.

Eli Lilly has been a terrific stock to own for the past five years, thanks to its excellent clinical and regulatory progress.

Eli Lilly may appeal to investors for its pill version of tirzepatide—likely on the horizon in 2026—as well as for its oncology products. Indeed, the company's pipeline is impressive overall.

Furthermore, Tewari cites the company’s robust pipeline ... Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is ...

The robust pipeline is a result of Lilly's strong ... non-GAAP net income (on the high end relative to peers based on Lilly’s product portfolio being more prone to possible litigation).